Nucleai

We’re pleased to announce results from our collaborative work with Bio-Techne and Lunaphore, featuring new data from the SECOMBIT clinical trial to be shared at he Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting.

The study demonstrates how Nucleai’s AI-powered multimodal platform, combined with Bio-Techne’s high-plex spatial biology technology, can identify predictive biomarkers in melanoma patients treated with immunotherapy and targeted therapies.

By integrating high-plex spatial proteomics with AI-driven multimodal analysis, the research translates complex tumor data into actionable insights for drug development and diagnostics.

We’re honored that this research was selected among the top 150 abstracts at this year’s meeting, underscoring the meaningful progress in applying spatial biology and AI to advance precision medicine.
Read the full press release👉 https://bit.ly/4oVkk4D

We’re honored to be named one of the Top 10 Companies of 2025 by Genetic Engineering & Biotechnology News for the third year in a row.

This year marks an especially meaningful milestone as we launched our first-of-its-kind deep learning model to automate the normalization of high-plex imaging data and showcased our OD-based quantitative biomarker scoring solution, advancing biomarker discovery for ADCs, bispecifics, and immunotherapies and making spatial biology more actionable for clinical and translational research.

A big thank-you to our team, partners, and collaborators driving innovation forward.

https://bit.ly/3VY11Ls

𝐇𝐨𝐰 𝐜𝐚𝐧 𝐰𝐞 𝐛𝐞𝐭𝐭𝐞𝐫 𝐩𝐫𝐞𝐝𝐢𝐜𝐭 𝐰𝐡𝐢𝐜𝐡 𝐩𝐚𝐭𝐢𝐞𝐧𝐭𝐬 𝐰𝐢𝐥𝐥 𝐛𝐞𝐧𝐞𝐟𝐢𝐭 𝐟𝐫𝐨𝐦 𝐇𝐄𝐑2-𝐭𝐚𝐫𝐠𝐞𝐭𝐞𝐝 𝐀𝐃𝐂𝐬?
A new 𝘊𝘢𝘯𝘤𝘦𝘳 𝘊𝘦𝘭𝘭 study demonstrates how combining spatial biomarkers with an AI-powered approach could identify novel markers of efficacy—helping to stratify patients and guide treatment decisions.
In our latest blog, we break down the findings and share how Nucleai is redefining ADC research with high-resolution, optical density-based IHC quantification and spatial analysis capabilities that provide deeper insights into how ADCs work, why resistance may occur, and which patients are most likely to benefit.

👉 Read the full blog: https://hubs.ly/Q03KQFnH0